endometrial serous adenocarcinoma (Cancer)
Information
- Disease name
- endometrial serous adenocarcinoma
- Disease ID
- DOID:5750
- Description
- "A uterine corpus cancer that is characterized histologically by papillae with fibrovascular cores, marked nuclear atypia, psammoma bodies and cilia." [url:http\://en.wikipedia.org/wiki/Uterine_serous_carcinoma]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03660826 | Active, not recruiting | Phase 2 | Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone | September 27, 2018 | December 31, 2024 |
| NCT03914612 | Active, not recruiting | Phase 3 | Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer | July 16, 2019 | May 10, 2024 |
| NCT00942357 | Active, not recruiting | Phase 3 | Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer | June 29, 2009 | July 28, 2024 |
| NCT01737619 | Active, not recruiting | N/A | PET/CT and Lymph Node Mapping in Finding Lymph Node Metastasis in Patients With High-Risk Endometrial Cancer | April 3, 2013 | April 30, 2025 |
| NCT01935934 | Active, not recruiting | Phase 2 | Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer | April 29, 2013 | March 26, 2025 |
| NCT00977574 | Active, not recruiting | Phase 2 | Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer | September 14, 2009 | March 6, 2025 |
| NCT02020707 | Active, not recruiting | Phase 1 | Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers | February 24, 2014 | June 30, 2025 |
| NCT02874430 | Active, not recruiting | Phase 2 | Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer | June 8, 2016 | June 2023 |
| NCT02142803 | Active, not recruiting | Phase 1 | TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors | May 20, 2014 | October 1, 2024 |
| NCT01210222 | Completed | Phase 2 | Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer | June 6, 2011 | July 16, 2016 |
| NCT01225887 | Completed | Phase 2 | Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer | October 2011 | January 2016 |
| NCT01307631 | Completed | Phase 2 | Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer | March 2011 | September 18, 2015 |
| NCT01440998 | Completed | Phase 1 | Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer | September 20, 2011 | December 31, 2015 |
| NCT01642082 | Completed | Phase 2 | Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer | September 2012 | January 2016 |
| NCT01935973 | Completed | Phase 1 | Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer | September 30, 2013 | September 8, 2015 |
| NCT00005830 | Completed | Phase 1 | Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer | July 2000 | |
| NCT00005840 | Completed | Phase 1 | Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer | July 2000 | |
| NCT00006011 | Completed | Phase 3 | Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer | July 2000 | |
| NCT00478426 | Completed | Phase 2 | Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer | April 30, 2007 | February 12, 2019 |
| NCT00575952 | Completed | Phase 1 | Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer | January 17, 2008 | July 16, 2016 |
| NCT00888173 | Completed | Phase 2 | Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer | July 6, 2009 | July 16, 2016 |
| NCT01005329 | Completed | Phase 2 | Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer | November 6, 2009 | September 22, 2013 |
| NCT01010126 | Completed | Phase 2 | Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer | September 8, 2009 | March 13, 2017 |
| NCT01132820 | Completed | Phase 2 | Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer | June 2010 | January 2016 |
| NCT02315469 | Completed | Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery | February 10, 2015 | February 9, 2019 | |
| NCT02501954 | Completed | Phase 3 | Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol | March 2015 | November 2023 |
| NCT02728258 | Completed | Phase 2 | Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer | September 16, 2016 | February 14, 2020 |
| NCT01344837 | Not yet recruiting | Biomarkers in Blood and Tissue Samples From Patients With Uterine Cancer | January 2100 | ||
| NCT03422198 | Recruiting | Phase 3 | Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer | January 30, 2018 | October 31, 2029 |
| NCT05498597 | Recruiting | Phase 1 | AMT-151 in Patients With Selected Advanced Solid Tumours | January 25, 2023 | October 30, 2024 |
| NCT04494113 | Recruiting | Early Phase 1 | Testing the Response to the Anti-cancer Drug, Triapine, in Uterine Cancers Using Markers From the Tissue at the Time of Hysterectomy | February 8, 2022 | November 10, 2024 |
| NCT05049538 | Recruiting | Determine the Utility of Liquid Biopsies and Tumor Molecular Profiling in Predicting Recurrence in High-Risk Endometrial Cancers | June 18, 2019 | June 30, 2024 | |
| NCT05256225 | Recruiting | Phase 2/Phase 3 | Testing the Addition of Trastuzumab or Trastuzumab/Pertuzumab to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma | November 16, 2022 | October 31, 2027 |
| NCT04585958 | Suspended | Phase 1 | Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Endometrial Cancer | May 21, 2021 | June 30, 2024 |
| NCT02112552 | Terminated | Phase 2 | Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation Therapy in Treating Patients With Stage IIIC-IV Uterine Cancer | April 10, 2014 | December 1, 2017 |
| NCT02065687 | Unknown status | Phase 2/Phase 3 | Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer | March 17, 2014 | September 13, 2023 |
| NCT00807768 | Unknown status | Phase 3 | Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer | March 23, 2009 | |
| NCT03836157 | Withdrawn | Phase 2 | Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer | May 31, 2019 | May 2022 |
- Disase is a (Disease Ontology)
- DOID:9460
- Cross Reference ID (Disease Ontology)
- NCI:C27838
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0854924
- Exact Synonym (Disease Ontology)
- uterine corpus serous adenocarcinoma
- Exact Synonym (Disease Ontology)
- uterine papillary serous carcinoma
- Exact Synonym (Disease Ontology)
- uterine serous carcinoma